Table 1.
Demographic and clinical features of COVID-19 patients recruited in this study.
| Total | Mild | Severe (survivor) | Severe (non-survivor) | P value | |
|---|---|---|---|---|---|
| Cases | 344 | 120 | 175 | 49 | / |
| Age (Years) | |||||
| Median (IQR)* | 53 (44–64) | 47 (38–55) | 56 (46–65) | 65 (55.5–73) | <0.0001 |
| Gender, n (%) | |||||
| Male | 209 (608) | 70 (58.3) | 107 (61.1) | 33 (67.3) | 0.5515 |
| Female | 135 (39.2) | 50 (41.7) | 68 (38.9) | 16 (32.7) | 0.5515 |
| Underlying diseases, n (%) | |||||
| Yes | 191 (55.5) | 40 (33.3) | 111 (63.4) | 40 (81.6) | <0.0001 |
| Hypertension | 101 (29.4) | 17 (14.2) | 64 (36.6) | 20 (40.8) | <0.0001 |
| Diabetes | 34 (9.9) | 3 (2.5) | 23 (13.1) | 8 (16.3) | 0.00286 |
| Heart disease | 33 (9.6) | 11 (9.2) | 16 (9.1) | 6 (12.2) | 0.7932 |
| Cerebrovascular disease | 18 (5.2) | 5 (4.2) | 9 (5.1) | 4 (8.2) | 0.5694 |
| Chronic kidney disease | 11 (3.2) | 2 (1.7) | 6 (3.4) | 3 (6.1) | 0.3178 |
| Malignancies | 8(2.3) | 1 (0.83) | 5 (2.9) | 0 (0.0) | 0.2572 |
| Chronic respiratory diseases | 6 (1.7) | 2 (1.7) | 3 (1.7) | 1 (2.0) | 0.985 |
| Symptoms, n (%) | |||||
| Fever | 305 (88.7) | 98 (81.7) | 160 (91.4) | 47 (95.9) | <0.0001 |
| Dyspnoea | 68 (19.8) | 22 (18.3) | 25 (14.3) | 21 (42.9) | <0.0001 |
| Fatigue | 82 (23.8) | 19 (15.8) | 44 (25.1) | 19 (38.8) | 0.0054 |
| Cough | 274 (79.7) | 85 (70.8) | 148 (84.6) | 41 (83.7) | 0.0119 |
| Pharyngalgia | 28 (8.1) | 8 (6.7) | 11 (6.3) | 9 (18.4) | 0.0231 |
| Muscle pain | 57 (16.6) | 19 (15.8) | 26 (14.9) | 12 (24.5) | 0.2669 |
| Headache | 34 (9.9) | 14 (11.7) | 14 (8.0) | 6 (12.2) | 0.4887 |
| Diarrhea | 10 (2.9) | 3 (2.5) | 6 (3.4) | 1 (2.0) | 0.8314 |
Note: P values were calculated by Kruskal–Wallis test or χ2 test as appropriate. *IQR, interquartile range.